Ischemix

Ischemix is a privately held drug development company. The company's primary focus is the development of the lead compound CMX-2043 for the treatment of TBI. Ischemix is developing novel, proprietary cytoprotective compounds for the treatment of serious diseases and conditions. Our lead compound CMX-2043 is in preclinical development for the treatment of traumatic brain injury (TBI).